5313492025-10-012025-12-315313492025-12-315313492025-04-012025-12-315313492025-10-012025-12-31in-capmkt:OtherExpenses1Member5313492025-04-012025-12-31in-capmkt:OtherExpenses1Member5313492025-10-012025-12-31in-capmkt:ReportableSegments1Member5313492025-10-012025-12-31in-capmkt:ReportableSegments2Member5313492025-04-012025-12-31in-capmkt:ReportableSegments1Member5313492025-04-012025-12-31in-capmkt:ReportableSegments2Member5313492025-10-012025-12-31in-capmkt:ReportableSegments1Member5313492025-10-012025-12-31in-capmkt:ReportableSegments2Member5313492025-04-012025-12-31in-capmkt:ReportableSegments1Member5313492025-04-012025-12-31in-capmkt:ReportableSegments2Member5313492025-10-012025-12-31in-capmkt:ReportableSegments1Member5313492025-12-31in-capmkt:ReportableSegments1Member5313492025-10-012025-12-31in-capmkt:ReportableSegments2Member5313492025-12-31in-capmkt:ReportableSegments2Member5313492025-10-012025-12-31in-capmkt:ReportableSegments1Member5313492025-12-31in-capmkt:ReportableSegments1Member5313492025-10-012025-12-31in-capmkt:ReportableSegments2Member5313492025-12-31in-capmkt:ReportableSegments2Member5313492025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15313492025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares531349PANACEABIONOTLISTEDINE922B01023Panacea Biotec LimitedMain BoardEquity2025-04-012026-03-312026-02-112026-02-02INRLakhsQuarterlyThird quarterMulti segment2026-02-1115:30:002026-02-1118:45:00Not applicable2025-10-012025-12-31UnauditedConsolidated165190000022800000167470000090170000023800000-24620000040530000018500000845000004499000001637500000372000002770000064900000500000255000002600000003890000000003890000046000004350000039800000-90000044400000-9000006130000010.650.65000.650.65Notes: <BR> 1. The financial results for the quarter and nine months ended December 31, 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 11, 2026, and have been reviewed by the statutory auditors of the Company. <BR> 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. <BR> 3. The consolidated financial results of the Company have been prepared by consolidating the reviewed financial results of the Company and its material subsidiary for the respective periods, with the management approved financial results of other wholly owned subsidiaries (“WOS”) and the Enterprises over which the Company exercises control (the Company, these subsidiaries and the enterprises hereinafter collectively referred to as “the Group”): <BR> (i) Indian WOS: Panacea Biotec Pharma Limited (“PBPL”) (material subsidiary) and Meyten Realtech Private Limited; <BR> (ii) Overseas WOS: Panacea Biotec (International) S.A. (“PBS”), Panacea Biotec Germany GmbH (WOS through PBS) and Panacea Biotec Inc. (WOS through PBPL); and <BR> (iii) Enterprises over which the Company exercises control*: PanEra Biotec Private Limited and Adveta Power Private Limited. <BR> *considered as a subsidiary for the purpose of consolidation as per Ind AS 110 <BR> 4. For the nine months ended December 31, 2025, the Company has incurred loss (before tax and exceptional items) of Rs.3,924 Lakh (nine months ended December 31,2024: loss of Rs.403 Lakh) and the Group has incurred a loss (before tax and exceptional items) of Rs. 2,291 Lakh (nine months ended December 31, 2024: loss of Rs.1,619 Lakh). The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis. <BR> 5. During the nine months ended December 31, 2025, the Group has recognised an exceptional income of Rs. 1,679 Lakh under the “Exceptional Item” in the consolidated statement of profit and loss, which includes: <BR> (i) revenue of Rs. 858 Lakh (nine months ended December 31, 2024: Nil), pursuant to the settlement agreement dated July 9, 2025 executed with Apotex Inc., USA <BR> (“Apotex”) to settle the ongoing dispute between Apotex and the Company & PBPL; and <BR> (ii) revenue of Rs. 821 Lakh (nine months ended December 31, 2024: Rs. 828 lakh), out of the remaining deferred consideration of Rs. 2,111 Lakh as at March 31, 2025, from sale of domestic pharmaceutical brands of PBPL. The balance deferred consideration of Rs. 1,290 Lakh (December 30, 2024: Rs. 4,882 Lakh) would be recognised in subsequent quarters / years and is shown as Contract Liability in the consolidated financial statements of the Group. <BR> 6. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (‘Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages. The incremental impact of these changes, assessed by the Company / Group, on the basis of the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, has been accounted for accordingly. Once Central / State Rules are notified by the Government on all aspects of the Codes, the Company / Group will evaluate additional impact, if any, on the measurement of employee benefits and would provide appropriate accounting effect. <BR> 2025-04-012025-12-31UnauditedConsolidated47302000001435000004873700000209460000063000000-11670000013396000004850000025180000014220000005102800000-229100000167900000-61200000800000-4000004000000-616000000000-616000004300000-57300000-58900000-2700000-54600000-2700000613000001-0.97-0.9700-0.97-0.97Other Expenses449900000Other Expenses1422000000Vaccines992400000Formulations659500000Vaccines3023000000Formulations1707200000165190000047302000000016519000004730200000Vaccines-25700000Formulations90600000Vaccines-233900000Formulations17270000064900000-61200000000064900000-61200000Vaccines8968600000Formulations403400000013002600000013002600000Vaccines3353700000Formulations13682000004721900000047219000007. The Company publishes standalone financial results along with consolidated financial results. In accordance with Ind AS 108 ‘Operating Segments’, the management has disclosed the segment information in the consolidated financial results of the Group for the nine months ended December 31, 2025. <BR> 8. The necessary certificate / report in respect of the above results in terms of the requirements of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors. <BR> 9. Previous period amounts have been regrouped / reclassified in compliance with Ind-AS to make them comparable with those of current period / year. <BR> 10. ‘0’ under “Rs. in Lakh” represents an amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. <BR> 11. The above results are also available on the Company’s website https://www.panaceabiotec.com <BR> Items that will not be reclassified to Profit or loss61000006100000Items that will not be reclassified to Profit or loss570000057000001500000140000046000004300000